Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
· for investor and media inquiries:
Source Summary
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem Oncology to report progress across the VS-7375 oral KRAS G12D (ON/OFF) TARGET-D program and updated Phase 1/2 TARGET-D 101 data.
Advertisement